Introduction
According to TechSci Research, the Global Primary Immunodeficiency Disorders (PIDD) Market, valued at USD 7.03 billion in 2023, is projected to grow to USD 9.88 billion by 2029, registering a CAGR of 6.01% during the forecast period. PIDD, a group of over 400 rare, chronic disorders caused by inherited genetic mutations, demands innovative therapeutic solutions and precise diagnostics.
This report explores emerging trends, growth drivers, the regulatory landscape, competitive analysis